がん標的治療の世界市場

がん標的治療の世界市場は2030年までに232億米ドルに達する見込み

2024年に161億米ドルと推定されるがん標的治療の世界市場は、分析期間2024-2030年にCAGR 6.4%で成長し、2030年には232億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるホルモン療法は、CAGR 8.0%を記録し、分析期間終了時には70億米ドルに達すると予測されます。モノクローナル抗体分野の成長率は、分析期間のCAGRで7.1％と推定されます。

米国市場は44億米ドルと推定、中国はCAGR 10.3％で成長予測

米国のがん標的治療市場は、2024年に44億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに48億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と6.3％と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界のがん標的治療市場動向と促進要因まとめ

腫瘍の特定の分子ドライバーを攻撃するがん標的治療は、現在、腫瘍学イノベーションの最前線に立っています。

ゲノムプロファイリング、特に次世代シーケンシングの進歩により、臨床医は患者を特定の遺伝子変異を阻害する治療法に適合させることができるようになりました。このような治療は、全身毒性を抑え、有効性を高めることができるため、一般的な化学療法よりもますます好まれるようになっています。この分野は、製薬会社が、抗体薬物複合体、キナーゼ阻害剤、放射性医薬品のような技術を用いて、狭いがんサブタイプに焦点を当てた薬剤を開発するにつれて、成長を続けています。公衆衛生機関やNGOも、早期発見と個別化治療計画を奨励するイニシアチブを支援しており、より幅広い治療へのアクセスと採用に貢献しています。

どのような技術革新が採用を後押ししているのか？

抗体薬物複合体は、細胞傷害性薬剤を腫瘍細胞に直接送達し、オフターゲット効果を低減することで、プレシジョン・オンコロジーを再定義しています。放射性医薬品もまた、特に固形がんや転移性疾患における治療パラダイムを変革しています。人工知能は、より効果的なバイオマーカー発見、患者層別化、試験デザインを可能にしています。同時に、リキッドバイオプシーなどの新しい診断技術は、非侵襲的でリアルタイムのがん進行モニタリングを提供します。これらは、早期承認やアクセスプログラムを支援する規制の枠組みによって補完されているが、コストや公平性に関する課題は多くの地域で依然として根強く残っています。

がん標的治療市場の成長はいくつかの要因によってもたらされる...

がん標的治療市場の成長は、ゲノミクス、治療法の進歩、システム全体の採用に関連するいくつかの要因によって牽引されています。世界のがん負担の増加により、より個別化された効果的なソリューションに対する需要が拡大しています。ゲノムスクリーニング機能の向上により、精密治療の対象となる人口が拡大しています。放射性医薬品や生物製剤のような新たな治療法は、治療範囲を拡大しています。人工知能や機械学習ツールは、治療のマッチングや医薬品開発を改善しています。さらに、戦略的提携や革新的な支払いモデルが、アクセスの障壁を克服し、多様なヘルスケアシステムでの採用を後押ししています。

セグメント

治療タイプ（ホルモン療法、モノクローナル抗体、シグナル伝達阻害剤、遺伝子発現調節剤、アポトーシス阻害剤、その他の治療タイプ）、適応疾患（肺がん、乳がん、大腸がん、白血病、黒色腫、リンパ腫、その他のがん適応疾患）、エンドユーザー（病院・診療所エンドユーザー、がん・放射線治療センターエンドユーザー、学術・研究機関エンドユーザー）

調査対象企業の例

• AbbVie Inc.
• Addex Therapeutics Ltd.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeOne Medicines（BeiGene）
• BioNTech SE
• Bristol-Myers Squibb Company
• Contera Pharma
• Daiichi Sankyo Co., Ltd.
• GSK plc.
• ImmunoGen, Inc.
• Merck & Co., Inc.
• Mirati Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Roche（F. Hoffmann-La Roche Ltd.）
• Sanofi
• Seagen, Inc.
• Takeda Pharmaceutical Co. Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Targeted Cancer Therapy Market to Reach US$23.2 Billion by 2030

The global market for Targeted Cancer Therapy estimated at US$16.1 Billion in the year 2024, is expected to reach US$23.2 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 10.3% CAGR

The Targeted Cancer Therapy market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Targeted Cancer Therapy Market - Key Trends & Drivers Summarized

Targeted cancer therapy, which attacks specific molecular drivers in tumors, now stands at the forefront of oncology innovation.

Advances in genomic profiling-especially next-generation sequencing-enable clinicians to match patients with therapies that inhibit specific genetic mutations. These treatments are increasingly preferred over generalized chemotherapy due to their ability to limit systemic toxicity and increase efficacy. The segment continues to grow as pharmaceutical companies develop drugs focused on narrow cancer subtypes, often using technologies like antibody-drug conjugates, kinase inhibitors, and radiopharmaceuticals. Public health bodies and NGOs are also supporting initiatives that encourage early detection and personalized treatment planning, contributing to broader therapy access and adoption.

What Technological Innovations Are Boosting Adoption?

Antibody-drug conjugates are redefining precision oncology by delivering cytotoxic agents directly to tumor cells, reducing off-target effects. Radiopharmaceuticals are also transforming treatment paradigms, particularly in solid tumors and metastatic conditions. Artificial intelligence is enabling more effective biomarker discovery, patient stratification, and trial design. In tandem, new diagnostic techniques such as liquid biopsies offer non-invasive, real-time monitoring of cancer progression. These are complemented by regulatory frameworks that support accelerated approvals and access programs, although challenges related to cost and equity remain prevalent in many regions.

The Growth in the Targeted Cancer Therapy Market Is Driven by Several Factors…

The growth in the targeted cancer therapy market is driven by several factors related to genomics, therapeutic advancement, and system-wide adoption. The increasing global cancer burden is expanding demand for more personalized and effective solutions. Improved genomic screening capabilities have expanded the population eligible for precision therapies. Emerging modalities like radiopharmaceuticals and biologics are expanding treatment scope. Artificial intelligence and machine learning tools are improving treatment matching and drug development. Additionally, strategic collaborations and innovative payment models are helping overcome access barriers and drive adoption across diverse healthcare systems.

SCOPE OF STUDY:

The report analyzes the Targeted Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Other Therapy Types); Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications); End-Use (Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use, Academic & Research Institutions End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AbbVie Inc.
• Addex Therapeutics Ltd.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeOne Medicines (BeiGene)
• BioNTech SE
• Bristol-Myers Squibb Company
• Contera Pharma
• Daiichi Sankyo Co., Ltd.
• GSK plc.
• ImmunoGen, Inc.
• Merck & Co., Inc.
• Mirati Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Roche (F. Hoffmann-La Roche Ltd.)
• Sanofi
• Seagen, Inc.
• Takeda Pharmaceutical Co. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted Cancer Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cancer Globally Fuels Demand for Personalized, Targeted Treatment Approaches
  • Advancements in Genomic Profiling and Biomarker Identification Drive Targeted Therapy Innovation
  • Expansion of Indications for Monoclonal Antibodies and TKIs Enhances Market Penetration
  • Increased Adoption of Companion Diagnostics Supports Precise Patient Selection and Dosing
  • Clinical Success in Immuno-Oncology Combinations Strengthens Interest in Synergistic Approaches
  • Shift Away From Cytotoxic Chemotherapy Toward Targeted Modalities Drives Treatment Paradigm Shift
  • Growth in Cancer Subtype-Specific Drug Development Fuels Investment in Rare Oncology Indications
  • Regulatory Accelerated Approvals Based on Biomarker Response Spur Fast-Track Commercialization
  • Rise in Liquid Biopsy Use Enhances Detection and Real-Time Monitoring of Therapy Effectiveness
  • Demand for Oral and Self-Administered Targeted Agents Supports Outpatient Cancer Management
  • Growing Use of AI in Drug Discovery Accelerates Pipeline for Mutation-Specific Therapeutics
  • Expanded Use of Real-World Evidence in Oncology Trials Supports Broader Indication Labeling
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted Cancer Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Targeted Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Signal Transduction Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Signal Transduction Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Signal Transduction Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gene Expression Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gene Expression Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Gene Expression Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Apoptosis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Apoptosis Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Apoptosis Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Cancer Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Cancer Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Other Cancer Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Cancer & Radiation Therapy Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Cancer & Radiation Therapy Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Cancer & Radiation Therapy Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Academic & Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for Academic & Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: USA 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• JAPAN
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• CHINA
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• EUROPE
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Targeted Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Europe 16-Year Perspective for Targeted Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• FRANCE
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: France 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: France 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: France 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• GERMANY
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Germany 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: Germany 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Germany 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Italy 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Italy 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Italy 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 128: UK Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: UK 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: UK 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 134: UK Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: UK 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Spain 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Spain 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 143: Spain Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Spain Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Spain 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Russia 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Russia 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 152: Russia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Russia Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Russia 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Rest of Europe Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Rest of Europe 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Targeted Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Asia-Pacific Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Australia 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Australia 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 182: Australia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Australia Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Australia 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• INDIA
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 185: India Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: India 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: India 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 191: India Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: India Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: India 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: South Korea 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: South Korea 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 200: South Korea Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: South Korea Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: South Korea 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Asia-Pacific Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Asia-Pacific 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Targeted Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Latin America 16-Year Perspective for Targeted Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Latin America 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Latin America 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 221: Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Latin America Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Latin America 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Argentina 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Argentina 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 230: Argentina Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Argentina Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Argentina 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Brazil 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Brazil 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 239: Brazil Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Brazil Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Brazil 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Mexico 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Mexico 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 248: Mexico Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Mexico Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Mexico 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Latin America Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Rest of Latin America 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Targeted Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Middle East 16-Year Perspective for Targeted Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Middle East 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Middle East 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 269: Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Middle East Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Middle East 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Iran 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Iran 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 278: Iran Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Iran Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Iran 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Israel 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Israel 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 287: Israel Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Israel Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Israel 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Saudi Arabia Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Saudi Arabia 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: UAE 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: UAE 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 305: UAE Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: UAE Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: UAE 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Middle East Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Middle East 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030
• AFRICA
  • Targeted Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Targeted Cancer Therapy by Therapy Type - Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Africa 16-Year Perspective for Targeted Cancer Therapy by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors and Other Therapy Types for the Years 2014, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Targeted Cancer Therapy by Disease Indication - Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Africa 16-Year Perspective for Targeted Cancer Therapy by Disease Indication - Percentage Breakdown of Value Sales for Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications, Lung Cancer, Breast Cancer and Colorectal Cancer for the Years 2014, 2025 & 2030
  • TABLE 323: Africa Recent Past, Current & Future Analysis for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Africa Historic Review for Targeted Cancer Therapy by End-Use - Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Africa 16-Year Perspective for Targeted Cancer Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use and Academic & Research Institutions End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION